Pascale Benlian

Pascale Benlian

Auto-generated profile, based on publicly available information

Pascale Benlian

Department of Biochemistry and Molecular Biology, Hôpital Saint Antoine, Paris, France

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2012 in European Heart Journal
Verified
Journal Article
Open access
PDF file
JPJoep Perk
Joep Perk
GBGuy De Backer
Guy De Backer
HGHelmut Gohlke
Helmut Gohlke
IGIan Graham
Ian Graham
ŽRŽeljko Reiner
Željko Reiner
DRDocument Reviewers
Document Reviewers
Atherosclerotic cardiovascular disease (CVD) is a chronic disorder developing insidiously throughout life and usually progressing to an advanced stage by the time symptoms occur. It remains the major cause of premature death in Europe, even though CVD mortality has fallen considerably over recent decades in many European countries. It is estimated that >80% of all CVD mortality now occurs in developing countries.

1 July 2012 in Atherosclerosis
Verified
Journal Article
Closed access
JPJoep Perk
Joep Perk
GBGuy De Backer
Guy De Backer
HGHelmut Gohlke
Helmut Gohlke
IGIan Graham
Ian Graham
ŽRŽeljko Reiner
Željko Reiner
FZFaiez Zannad
Faiez Zannad

24 October 2012 in International Journal of Behavioral Medicine
Verified
Journal Article
Closed access
PDF file
JPJoep Perk
Joep Perk
GBGuy De Backer
Guy De Backer
HGHelmut Gohlke
Helmut Gohlke
IGIan Graham
Ian Graham
ŽRŽeljko Reiner
Željko Reiner
D(Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)
Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)

4 July 2012 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
G(Guy De Backer1 (Belgium)
Guy De Backer1 (Belgium)
H(Helmut Gohlke1 (Germany)
Helmut Gohlke1 (Germany)
I(Ian Graham1 (Ireland)
Ian Graham1 (Ireland)
Ž(Željko Reiner2 (Croatia)
Željko Reiner2 (Croatia)
WNWm Monique Verschuren1 (The Netherlands)
Wm Monique Verschuren1 (The Netherlands)
F(Faiez Zannad1 (France)
Faiez Zannad1 (France)

1 August 2013 in Ophthalmology
Verified
Journal Article
Closed access
ESEric H. Souied
Eric H. Souied
CDCécile Delcourt
Cécile Delcourt
GQGiuseppe Querques
Giuseppe Querques
ABAna Bassols
Ana Bassols
BMBénédicte MJ Merle
Bénédicte MJ Merle
PBPascale Benlian
Pascale Benlian

1 March 2019 in Ophthalmology
Verified
Journal Article
Open access
JCJohanna M. Colijn
Johanna M. Colijn
AHAnneke I. Den Hollander
Anneke I. Den Hollander
Ayse DemirkanAyse Demirkan
Ayse Demirkan
ACAudrey Cougnard-Grégoire
Audrey Cougnard-Grégoire
TVTimo Verzijden
Timo Verzijden
MZMarkus Zumbansen
Markus Zumbansen
Genetic and epidemiologic studies have shown that lipid genes and high-density lipoproteins (HDLs) are implicated in age-related macular degeneration (AMD). We studied circulating lipid levels in relationship to AMD in a large European dataset. Pooled analysis of cross-sectional data. Individuals (N = 30 953) aged 50 years or older participating in the European Eye Epidemiology (E3) consortium and 1530 individuals from the Rotterdam Study with lipid subfraction data. AMD features were graded on fundus photographs using the Rotterdam classification. Routine blood lipid measurements, genetics, medication, and potential confounders were extracted from the E3 database. In a subgroup of the Rotterdam Study, lipid subfractions were identified by the Nightingale biomarker platform. Random-intercepts mixed-effects models incorporating confounders and study site as a random effect were used to estimate associations. AMD features and stage; lipid measurements. HDL was associated with an increased risk of AMD (odds ratio [OR], 1.21 per 1-mmol/l increase; 95% confidence interval [CI], 1.14-1.29), whereas triglycerides were associated with a decreased risk (OR, 0.94 per 1-mmol/l increase; 95% CI, 0.91-0.97). Both were associated with drusen size. Higher HDL raised the odds of larger drusen, whereas higher triglycerides decreases the odds. LDL cholesterol reached statistical significance only in the association with early AMD (P = 0.045). Regarding lipid subfractions, the concentration of extra-large HDL particles showed the most prominent association with AMD (OR, 1.24; 95% CI, 1.10-1.40). The cholesteryl ester transfer protein risk variant (rs17231506) for AMD was in line with increased HDL levels (P = 7.7 × 10-7), but lipase C risk variants (rs2043085, rs2070895) were associated in an opposite way (P = 1.0 × 10-6 and P = 1.6 × 10-4). Our study suggested that HDL cholesterol is associated with increased risk of AMD and that triglycerides are negatively associated. Both show the strongest association with early AMD and drusen. Extra-large HDL subfractions seem to be drivers in the relationship with AMD, and variants in lipid genes play a more ambiguous role in this association. Whether systemic lipids directly influence AMD or represent lipid metabolism in the retina remains to be answered.